Targeting Interleukin-4 Receptor Alpha by Hybrid Peptide for Novel Biliary Tract Cancer Therapy

Table 2

Combination therapy of hybrid peptide and GEM.

	IC50	CI
IL-4R hybrid peptide (μM)	4.47
Gemcitabine (nM)	12.2
IL-4R hybrid peptide (μM) + gemcitabine 0.3 nM	4.29	0.95
IL-4R hybrid peptide (μM) + gemcitabine 3 nM	3.25	0.75

CI (combination index) < 1, CI = 1, and CI > 1 indicate synergistic, addictive, and antagonistic effect, respectively.